DPP-4
Boehringer cheered by diabetes data
June 28, 2010Research and Development Boehringer, DPP-4, diabetes, linagliptin
Boehringer Ingelheim has been cheered by phase III data showing its new oral once-daily type II diabetes tablet linagliptin significantly …
Five-year cardiovascular study planned for Onglyza
March 10, 2010Research and Development, Sales and Marketing DPP-4, Onglyza, diabetes
Bristol-Myers Squibb and AstraZeneca are to embark on a five-year study of Onglyza in type II diabetes patients who may …
Boehringer prepares for diabetes launch
December 3, 2009Medical Communications Boehringer, DPP-4, diabetes
Boehringer Ingelheim has hired the London arm of international PR agency Weber Shandwick to handle the UK launch of its …
AZ-BMS launch Onglyza in Europe
October 19, 2009Sales and Marketing AZ, BMS, DPP-4, Onglyza, diabetes
Bristol-Myers Squibb and AstraZeneca’s long-awaited type II diabetes drug Onglyza has been launched in the UK, its first European market.Designed …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
